1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Montelukast Tablet Formulation

Manufacturer or supplier’s details
Company: Organon & Co.
Address: 30 Hudson Street, 33nd floor
Jersey City, New Jersey, U.S.A 07302
Telephone: 551-430-6000
Emergency telephone number: 215-631-6999
E-mail address: EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

2. HAZARDS IDENTIFICATION

Emergency Overview

<table>
<thead>
<tr>
<th>Appearance</th>
<th>tablet</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colour</td>
<td>coloured</td>
</tr>
<tr>
<td>Odour</td>
<td>odourless</td>
</tr>
</tbody>
</table>

Not a hazardous substance or mixture.

GHS Classification
Not a hazardous substance or mixture.

GHS label elements
Not a hazardous substance or mixture.

Physical and chemical hazards
Not classified based on available information.

Health hazards
Not classified based on available information.

Environmental hazards
Not classified based on available information.

Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture: Mixture
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Montelukast Tablet Formulation

Version 2.15  Revision Date: 2020/10/02  SDS Number: 23071-00017  Date of last issue: 2020/03/23
Date of first issue: 2014/10/17

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>&gt;= 30 - &lt; 50</td>
</tr>
<tr>
<td>Montelukast</td>
<td>151767-02-1</td>
<td>&gt;= 1 - &lt; 10</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>&gt;= 1 - &lt; 10</td>
</tr>
<tr>
<td>Titanium dioxide</td>
<td>13463-67-7</td>
<td>&gt;= 0.1 - &lt; 1</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: Wash with water and soap. Get medical attention if symptoms occur.

In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media: Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
- Metal oxides

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
6. ACCIDENTAL RELEASE MEASURES

**Special protective equipment for firefighters**

In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

**6.1 Personal precautions, protective equipment and emergency procedures**

Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**6.2 Environmental precautions**

Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

**6.3 Methods and materials for containment and cleaning up**

Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

**Handling**

**Technical measures**

Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

**Local/Total ventilation**

Use only with adequate ventilation.

**Advice on safe handling**

Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

**Avoidance of contact**

Oxidizing agents

**Storage**

Oxidizing agents
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Montelukast Tablet Formulation

Version 2.15  Revision Date: 2020/10/02  SDS Number: 23071-00017  Date of last issue: 2020/03/23  Date of first issue: 2014/10/17

Conditions for safe storage:
Keep in properly labelled containers. Store in accordance with the particular national regulations.

Materials to avoid:
Do not store with the following product types:
Strong oxidizing agents

Packaging material:
Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>PC-TWA</td>
<td>10 mg/m³</td>
<td>CN OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Montelukast</td>
<td>151767-02-1</td>
<td>TWA</td>
<td>40 µg/m³</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>400 µg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>TWA (Inhalable particulate matter)</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable particulate matter)</td>
<td>3 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Titanium dioxide</td>
<td>13463-67-7</td>
<td>PC-TWA</td>
<td>8 mg/m³</td>
<td>CN OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Total dust)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Further information: G2B - Possibly carcinogenic to humans

Engineering measures:
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection:
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Particulates type

Eye/face protection:
Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection:
Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-
posable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hand protection

Material : Chemical-resistant gloves
Remarks : Consider double gloving.
Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : tablet
Colour : coloured
Odour : odourless
Odour Threshold : No data available
pH : No data available
Melting point/freezing point : No data available
Initial boiling point and boiling range : No data available
Flash point : Not applicable
Evaporation rate : No data available
Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids) : No data available
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapour pressure : No data available
Relative vapour density : No data available
10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions:
- May form explosive dust-air mixture during processing, handling or other means.
  Can react with strong oxidizing agents.
Conditions to avoid: Heat, flames and sparks.
Avoid dust formation.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity:
Not classified based on available information.

Components:

Cellulose:
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Montelukast Tablet Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.15</td>
<td>2020/10/02</td>
<td>23071-00017</td>
<td>2020/03/23</td>
<td>2014/10/17</td>
</tr>
</tbody>
</table>

### Acute inhalation toxicity
- Montelukast: LC50 (Rat): > 5.8 mg/l
  - Exposure time: 4 h
  - Test atmosphere: dust/mist

### Acute dermal toxicity
- Montelukast: LD50 (Rabbit): > 2,000 mg/kg

### Montelukast:
- Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
- LD50 (Mouse): > 5,000 mg/kg

### Magnesium stearate:
- Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg
  - Method: OECD Test Guideline 423
  - Assessment: The substance or mixture has no acute oral toxicity
  - Remarks: Based on data from similar materials

### Titanium dioxide:
- Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
- Acute inhalation toxicity: LC50 (Rat): > 6.82 mg/l
  - Exposure time: 4 h
  - Test atmosphere: dust/mist
  - Assessment: The substance or mixture has no acute inhalation toxicity

### Skin corrosion/irritation
Not classified based on available information.

### Components:

#### Montelukast:
- Species: Rabbit
- Result: Mild skin irritation

#### Magnesium stearate:
- Species: Rabbit
- Result: No skin irritation
- Remarks: Based on data from similar materials

#### Titanium dioxide:
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Montelukast Tablet Formulation

Version: 2.15  Revision Date: 2020/10/02  SDS Number: 23071-00017  Date of last issue: 2020/03/23
Date of first issue: 2014/10/17

Species: Rabbit  Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Montelukast:
Species: Rabbit  Result: Severe irritation

Magnesium stearate:
Species: Rabbit  Result: No eye irritation
Remarks: Based on data from similar materials

Titanium dioxide:
Species: Rabbit  Result: No eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Montelukast:
Remarks: No data available

Magnesium stearate:
Test Type: Maximisation Test  Exposure routes: Skin contact  Species: Guinea pig  Method: OECD Test Guideline 406  Result: negative  Remarks: Based on data from similar materials

Titanium dioxide:
Test Type: Local lymph node assay (LLNA)  Exposure routes: Skin contact  Species: Mouse  Result: negative

Germ cell mutagenicity
Not classified based on available information.
Montelukast Tablet Formulation

Components:

Cellulose:
Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
- Test Type: In vitro mammalian cell gene mutation test
  Result: negative

Genotoxicity in vivo:
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  Species: Mouse
  Application Route: Ingestion
  Result: negative

Montelukast:
Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
- Test Type: In vitro mammalian cell gene mutation test
  Test system: Chinese hamster fibroblasts
  Result: negative
- Test Type: Chromosomal aberration
  Test system: Chinese hamster ovary cells
  Result: negative
- Test Type: Alkaline elution assay
  Test system: rat hepatocytes
  Result: negative

Genotoxicity in vivo:
- Test Type: Chromosomal aberration
  Species: Mouse
  Cell type: Bone marrow
  Application Route: Oral
  Result: negative

Magnesium stearate:
Genotoxicity in vitro:
- Test Type: In vitro mammalian cell gene mutation test
  Result: negative
  Remarks: Based on data from similar materials
- Test Type: Chromosome aberration test in vitro
  Method: OECD Test Guideline 473
  Result: negative
  Remarks: Based on data from similar materials
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
  Remarks: Based on data from similar materials

Titanium dioxide:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Genotoxicity in vivo: Test Type: In vivo micronucleus test  
Species: Mouse  
Result: negative

Carcinogenicity  
Not classified based on available information.

Components:

Cellulose:  
Species: Rat  
Application Route: Ingestion  
Exposure time: 72 weeks  
Result: negative

Montelukast:  
Species: Rat  
Application Route: Oral  
Exposure time: 2 Years  
Result: negative  
Species: Mouse  
Application Route: Oral  
Exposure time: 92 weeks  
Result: negative

Titanium dioxide:  
Species: Rat  
Application Route: inhalation (dust/mist/fume)  
Exposure time: 2 Years  
Method: OECD Test Guideline 453  
Result: positive  
Remarks: The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assessment: Limited evidence of carcinogenicity in inhalation studies with animals.

Reproductive toxicity  
Not classified based on available information.

Components:

Cellulose:  
Effects on fertility: Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative
### Montelukast Tablet Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.15</td>
<td>2020/10/02</td>
<td>23071-00017</td>
<td>2020/03/23</td>
<td>2014/10/17</td>
</tr>
</tbody>
</table>

**Effects on foetal development**
- **Test Type:** Fertility/early embryonic development
- **Species:** Rat
- **Application Route:** Ingestion
- **Result:** negative

**Montelukast:**

**Effects on fertility**
- **Test Type:** Fertility
  - **Species:** Rat, male
  - **Application Route:** Oral
  - **Fertility:** NOAEL: 800 mg/kg body weight
  - **Result:** Animal testing did not show any effects on fertility.

  - **Test Type:** Fertility
    - **Species:** Rat, female
    - **Application Route:** Oral
    - **Fertility:** LOAEL: 200 mg/kg body weight
    - **Symptoms:** Reduced fertility

  - **Test Type:** Fertility
    - **Species:** Rat, female
    - **Application Route:** Oral
    - **Fertility:** NOAEL: 100 mg/kg body weight
    - **Symptoms:** Reduced fertility

**Magnesium stearate:**

**Effects on fertility**
- **Test Type:** Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
  - **Species:** Rat
  - **Application Route:** Ingestion
  - **Method:** OECD Test Guideline 422
  - **Result:** negative
  - **Remarks:** Based on data from similar materials

**Effects on foetal development**
- **Test Type:** Embryo-foetal development
  - **Species:** Rat
  - **Application Route:** Ingestion
  - **Result:** negative
  - **Remarks:** Based on data from similar materials

**STOT - single exposure**
Not classified based on available information.

**STOT - repeated exposure**
Not classified based on available information.

**Repeated dose toxicity**

**Components:**

**Cellulose:**
- **Species:** Rat
- **NOAEL:** >= 9,000 mg/kg
- **Application Route:** Ingestion
## Montelukast Tablet Formulation

### Exposure time
- 90 Days

### Montelukast:

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey, male and female</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>150 - 300 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>53 Weeks</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>50 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>53 Weeks</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Mouse</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>50 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>14 Weeks</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

### Magnesium stearate:

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>&gt; 100 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Ingestion</td>
</tr>
<tr>
<td>Exposure time</td>
<td>90 Days</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

### Titanium dioxide:

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>24,000 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Ingestion</td>
</tr>
<tr>
<td>Exposure time</td>
<td>28 Days</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>10 mg/m3</td>
</tr>
<tr>
<td>Application Route</td>
<td>inhalation (dust/mist/fume)</td>
</tr>
<tr>
<td>Exposure time</td>
<td>2 yr</td>
</tr>
</tbody>
</table>

### Aspiration toxicity
- Not classified based on available information.

### Experience with human exposure

### Components:

#### Montelukast:

- **Skin contact**: Remarks: May irritate skin.
- **Eye contact**: Symptoms: Severe irritation
- **Ingestion**: Symptoms: upper respiratory tract infection, pharyngitis, Headache, Cough, Abdominal pain, Diarrhoea, Fever
12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cellulose:
Toxicity to fish: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Montelukast:
Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): > 0.0778 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 0.0675 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants: NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity): NOEC (Pimephales promelas (fathead minnow)): 0.073 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210
Remarks: No toxicity at the limit of solubility

NOEC (Cyprinodon variegatus (sheepshead minnow)): 0.0816 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC (Daphnia magna (Water flea)): 0.23 mg/l
Exposure time: 21 d
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms: EC50: > 100 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility
Magasium stearate:
Toxicity to fish: LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
  Exposure time: 48 h
  Method: DIN 38412
  Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates: EL50 (Daphnia magna (Water flea)): > 1 mg/l
  Exposure time: 47 h
  Test substance: Water Accommodated Fraction
  Remarks: Based on data from similar materials
  No toxicity at the limit of solubility

Titanium dioxide:
Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
  Exposure time: 96 h
  Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 100 mg/l
  Exposure time: 48 h

Toxicity to algae/aquatic plants: EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l
  Exposure time: 72 h

Toxicity to microorganisms: EC50: > 1,000 mg/l
  Exposure time: 3 h
  Method: OECD Test Guideline 209
Montelukast Tablet Formulation

Persistence and degradability

Components:

Cellulose:
Biodegradability : Result: Readily biodegradable.

Montelukast:
Biodegradability : Result: not rapidly degradable
Biodegradation: 0 %
Exposure time: 28 d
Stability in water : Hydrolysis: 50 % (21.7 h)

Magnesium stearate:
Biodegradability : Result: Not biodegradable
Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Montelukast:
Partition coefficient: n-octanol/water : log Pow: > 4.3

Magnesium stearate:
Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil
No data available

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Montelukast Tablet Formulation

Version 2.15  Revision Date: 2020/10/02  SDS Number: 23071-00017

Date of last issue: 2020/03/23  Date of first issue: 2014/10/17

15. REGULATORY INFORMATION

National regulatory information
Law on the Prevention and Control of Occupational Diseases

The components of this product are reported in the following inventories:

<table>
<thead>
<tr>
<th>Inventory</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>AICS</td>
<td>not determined</td>
</tr>
<tr>
<td>DSL</td>
<td>not determined</td>
</tr>
<tr>
<td>IECSC</td>
<td>not determined</td>
</tr>
</tbody>
</table>

16. OTHER INFORMATION

Further information
Sources of key data used to compile the Safety Data Sheet

Date format: yyyy/mm/dd

Full text of other abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Text</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACGIH</td>
<td>USA. ACGIH Threshold Limit Values (TLV)</td>
</tr>
<tr>
<td>CN OEL</td>
<td>Occupational exposure limits for hazardous agents in the workplace - Chemical hazardous agents.</td>
</tr>
<tr>
<td>ACGIH / TWA</td>
<td>8-hour, time-weighted average</td>
</tr>
<tr>
<td>CN OEL / PC-TWA</td>
<td>Permissible concentration - time weighted average</td>
</tr>
</tbody>
</table>

All - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECX - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Montelukast Tablet Formulation

Version 2.15 Revision Date: 2020/10/02 SDS Number: 23071-00017 Date of last issue: 2020/03/23 Date of first issue: 2014/10/17

- International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Disclaimer
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN